Oxiracetam

Mild, energetic, "logical-analytical" racetam — Italy's Phase III/IV clinical heritage gave it a vascular-dementia label there, but the 2023 Korean phase IV trial (n=500) was negative and South Korea suspended it. For Dylan: optional PRN tool for coding/analytical days at 800 mg BID with citicoline/alpha-GPC cofactor; cleaner stim flavor than aniracetam, weaker than phenylpiracetam, no real downside risk at clinical doses. Don't make daily driver — the encyclopedia "logical thinking" framing is anecdote-heavy and the modern RCT signal is thin.

Oxiracetam is the 4-hydroxy analog of piracetam — a single hydroxyl group on the pyrrolidone ring is the entire structural difference, but it changes the pharmacology substantially: oxiracetam is roughly 2-4× more potent than piracetam by weight and has a markedly different subjective profile (energetic/analytical vs. piracetam's "blank" baseline lift).

1. AMPA receptor modulation — atypical PAM, not classical. Like other racetams, oxiracetam increases the maximal density of AMPA binding sites in the synaptic membrane rather than acting as a classical positive allosteric modulator (PAM) at the LBD-LBD interface (which is where aniracetam, CX-516, and the cyclothiazide-class ampakines bind). The 2009 Ahmed & Oswald work established that piracetam — and by extension, the racetam family — defines a new allosteric site distinct from the canonical aniracetam/CTZ/2-MeMePAM sites. Net result: AMPAR currents are mildly potentiated only when glutamate is present, with the effect being "facilitatory" rather than directly gating. A 2026 Cell Biochemistry & Biophysics paper (Springer, in-press) reports that oxiracetam modulates GluA1/GluA2 subunit kinetics in an AD model. Honest framing: the AMPA effect is real but weak compared to true PAMs — racetams' clinical effect sizes are correspondingly modest.

2. Cholinergic facilitation — release-side, K+-stimulated only. Spignoli & Pepeu (1987) showed that oxiracetam (and aniracetam) increase acetylcholine release from rat hippocampus only under K+-depolarization, not at rest. This is a "facilitate-when-active" mechanism — it amplifies an active cholinergic system without flooding it at baseline. Practical implication: pairs synergistically with choline donors (citicoline, alpha-GPC) because oxiracetam consumes choline for the upregulated ACh release; without cofactor, you get the classic racetam headache.

3. Glutamate + D-aspartate release potentiation. Oxiracetam additionally increases release of glutamate and D-aspartic acid from activated cortical neurons. This is the "glutamatergic" arm of the encyclopedia framing and contributes to the cortical-excitability flavor.

4. Phospholipid / membrane effects. Older work showed oxiracetam stabilizes phosphoinositide turnover and protects membrane phospholipid synthesis under hypoxic stress — likely mechanism behind the (stronger) preclinical neuroprotection signal in cerebral hypoperfusion / vascular models.

5. Glucose + ATP utilization. Increases regional cerebral glucose uptake and ATP production in stressed brain tissue (rat models). Modest effect; contributes to the "energetic" subjective flavor.

Pharmacokinetics:

• Oral bioavailability: ~70-80% (high; oxiracetam is small, polar, water-soluble)
• Tmax: 1-3 hours
• Half-life: ~8 hours in healthy young adults; 3-6 hours in elderly; 10-68 hours in renal impairment (this is the critical dosing flag)
• Distribution: Crosses BBB readily
• Metabolism: Minimal — ~84% excreted unchanged in urine. No significant hepatic metabolism, no major CYP involvement.
• Elimination: Renal (glomerular filtration + active secretion). Dose-adjust for eGFR <60 mL/min.
• Stereochemistry: Oxiracetam is sold as racemic mix. (S)-oxiracetam is the pharmacologically active enantiomer — phase I PK in healthy Chinese volunteers (Zhao et al. 2024) shows linear PK 200-2400 mg, ~55% urine recovery as unchanged S-form, well-tolerated.